Welcome to our dedicated page for Centessa Pharmaceuticals Plc SEC filings (Ticker: CNTA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Centessa Pharmaceuticals plc filings document the regulatory record of a clinical-stage pharmaceutical issuer with American Depositary Shares listed on Nasdaq, each representing one ordinary share. Disclosures cover its orexin receptor 2 (OX2R) agonist focus, operating and financial results, corporate presentations, risk and capital-structure matters, and securities registered in connection with the ADS program.
Centessa's SEC filings also include Form 8-K material-event reports for underwriting and at-the-market sales agreements, public offerings of ADSs, executive and board changes, employment and advisory arrangements, and Regulation FD materials. Proxy filings describe governance, shareholder voting matters, compensation topics, and related public-company controls.
Centessa Pharmaceuticals plc Chief People Officer Karen M. Anderson reported an exercise-and-sell transaction in the company’s Ordinary Shares. She exercised share options covering 109,398 Ordinary Shares at exercise prices of $4.01 and $3.85 per share, converting them into Ordinary Shares.
On the same date, she sold a total of 120,029 Ordinary Shares in open-market transactions at weighted average prices of $26.1505 and $27.1328 per share, pursuant to a pre-arranged Rule 10b5-1 trading plan adopted on November 12, 2025. Following these transactions, she directly holds 62,085 Ordinary Shares.
CNTA reports a Form 144 disclosing the intended sale of 64,768 ADRs by an issuer-related party on 03/16/2026. The filing lists 1,824,968.27 and an aggregate figure 134,447,836 on the cover and shows a prior reported sale of 120,029 ADRs on 03/13/2026.
Centessa Pharmaceuticals plc Chief People Officer Karen M. Anderson exercised stock options and sold shares in a planned transaction. She exercised options for 109,398 Ordinary Shares at an exercise price of $4.01 per share and received the same number of Ordinary Shares.
On the same date, she sold 107,961 Ordinary Shares at a weighted average price of $26.1505 and 12,068 Ordinary Shares at a weighted average price of $27.1328, in multiple trades within stated price ranges. These sales were made under a Rule 10b5-1 trading plan adopted on November 12, 2025.
After these transactions, Anderson directly holds 62,085 Ordinary Shares. The exercised option, originally granted with vesting beginning on December 1, 2023, is now fully exercised, and no remaining derivative position from this option is shown in this filing.
Centessa Pharmaceuticals Chief Business Officer Gregory M. Weinhoff sold 73,196 Ordinary Shares of CNTA in open-market transactions. The sales occurred on March 13, 2026 at weighted average prices of $26.1668 and $27.1570 per share across multiple trades within disclosed price ranges.
The transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 12, 2025, indicating they were scheduled in advance. Following these sales, Weinhoff continues to hold 65,925 Ordinary Shares directly.
CNTA reports a proposed sale of ADRs under Form 144. The filing lists 120,029 ADRs with an aggregate value of $3,103,949.94 and a filing date of 03/13/2026. The notice shows securities tied to an exercise of stock options (109,398 ADRs) on 03/13/2026 and vested RSUs (10,631 ADRs) dated 02/01/2026.
The broker/dealer named is UBS Financial Services Inc. in Weehawken, NJ, and the ADRs are traded on Nasdaq. This Form 144 is a regulatory notice of an intended sale; timing and final execution are determined by the selling holder and market conditions.
UBS Financial Services Inc. submitted a Form 144 for Common stock of CNTA, listing multiple RSU vesting entries with specific share counts and vest dates. The notice enumerates vest events dated between 09/30/2022 and 02/01/2026 with per‑event share quantities.
Centessa Pharmaceuticals plc reports a large institutional holder through an amended Schedule 13G. Avoro Capital Advisors LLC and Behzad Aghazadeh together report beneficial ownership of 14,555,555 American Depositary Shares (ADSs), representing 9.97% of the ordinary shares.
The percentage is based on 146,049,056 ordinary shares outstanding as referenced in a company prospectus supplement filed on November 13, 2025. The reporting persons state the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Centessa.
Centessa Pharmaceuticals plc outlines final arrangements with former Chief Executive Officer Saurabh Saha, M.D., Ph.D., following his previously disclosed departure effective January 1, 2026. On February 9, 2026, the company entered into an Advisory Agreement and a Separation Agreement with Dr. Saha.
Under the Advisory Agreement, Dr. Saha will provide advisory services for an initial six-month term, automatically continuing unless terminated, at an hourly fee of $376.00 plus reimbursed business expenses. The Separation Agreement provides vesting of equity grants scheduled to vest on or before February 2, 2026, with later-vesting equity forfeited, and an exercise period of three months after the advisory role ends.
The Separation Agreement also includes, subject to Compensation Committee approval, a bonus equal to 100% of Dr. Saha’s target bonus for the year ended December 31, 2025, and continued eligibility for applicable company benefit plans. These extended benefits replace other severance or noncompetition payments under prior agreements and are conditioned on a general release of claims becoming effective after a seven-business-day revocation period.
FMR LLC has filed an amended Schedule 13G reporting beneficial ownership of 10,999,793 shares of Centessa Pharmaceuticals plc common stock, representing 12.2% of the class. FMR LLC holds sole voting power over 10,988,411 shares and sole dispositive power over 10,999,793 shares.
Abigail P. Johnson is also listed as a reporting person with sole dispositive power over 10,999,793 shares but no voting power. The securities are certified as acquired and held in the ordinary course of business and not for the purpose of changing or influencing control of Centessa.
FMR LLC has filed an amended Schedule 13G reporting beneficial ownership of 8,894,939 shares of Centessa Pharmaceuticals plc common stock, representing 9.9% of the class as of the stated event date. FMR reports sole voting and dispositive power over these shares.
Abigail P. Johnson is also listed as a reporting person with sole dispositive power over the same 8,894,939 shares but no voting power. The filing states the shares are held in the ordinary course of business and not for the purpose of changing or influencing control, and that one or more other persons may receive dividends or sale proceeds, with no single such person holding more than five percent of the class.